Vol 6, No 3 (2013)
Prace poglądowe
Published online: 2013-10-11

open access

Page views 909
Article views/downloads 4037
Get Citation

Connect on Social Media

Connect on Social Media

Biopharmaceutics in nephrology

Tomasz Liberek, Wojciech Wołyniec, Marcin Renke, Ewa Weber, Bolesław Rutkowski
Forum Nefrologiczne 2013;6(3):139-149.

Abstract

Biopharmaceutics, are new group of therapeutics, designed and created by biotechnology. Their maintypes are recombinant proteins including monoclonal antibodies and fusion or chimeric proteins. They are characterized by specific and targeted actionand are mainly used in rheumatology, oncology, dermatology and gastroenterology. Recently, biopharmaceutics are increasingly used in nephrology and kidney transplantation. Up to now, rituximab — monoclonal, chimeric antibody against CD20, antigen present on lymphocytes is most commonly used in nephrology. It is used in treatment of many types primary glomerulonephritis, and, above all, in therapy of ANCA associated vasculitis and lupusnephritis.

Article available in PDF format

View PDF (Polish) Download PDF file